Press releases

February 4, 2019
Kyn Therapeutics Appoints Douglas Carlson as Chief Financial Officer

January 18, 2019
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies

December 19, 2018
Kyn Therapeutics Announces Initiation of Phase 1b/2 Clinical Studies of ARY-007 in Collaboration with Merck

March 21, 2018
Kyn Therapeutics Appoints Chairman and Scientific Advisory Board Member

December 14, 2017
Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

In the News

Despite Buyout, Celgene Dealmaking Rolls On With Kyn, Obsidian Tie-Ups

Endpoints News
Celgene inks first deals since Bristol-Myers announced $74B buyout — bets $80M on immunometabolism

Boston Business Journal
Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup

Bloomberg Baystate Business: Biogen, Budget and ESG

view all Tweets


Kyn has partnered with @Celgene to advance two of our immuno-oncology programs targeting critical… http://ag4kiXkf5L

Our lead clinical program targets the EP4 receptor in the prostaglandin E2 (PGE2) immunosuppressive axis in the tum… http://D4CRi2DP4T

It's #WorldCancerDay. At Kyn, we drive our field of #immunooncology research forward towards therapies that improve… http://lNJRU8CjyC

We're proud to welcome Doug Carlson, a highly experienced healthcare financial executive, as our chief financial of… http://7O8oOAtNTx

Media contact

Tom Donovan
Ten Bridge Communications


Sign up to get up-to-date news about Kyn Therapeutics.

Contact us

Find us

Kyn Therapeutics
50 Northern Avenue
7th Floor
Boston, MA 02210

Call us


Email us

Friend us